Y30 Stock Overview
MedBright AI Investments Inc. invests in healthcare technology companies.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
MedBright AI Investments Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.099 |
| 52 Week High | CA$0.11 |
| 52 Week Low | CA$0.079 |
| Beta | 0.22 |
| 1 Month Change | 11.66% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 27.23% |
| 5 Year Change | n/a |
| Change since IPO | -76.13% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| Y30 | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 6.7% | 4.0% | 1.9% |
| 1Y | n/a | 25.7% | 4.6% |
Return vs Industry: Insufficient data to determine how Y30 performed against the German Capital Markets industry.
Return vs Market: Insufficient data to determine how Y30 performed against the German Market.
Price Volatility
| Y30 volatility | |
|---|---|
| Y30 Average Weekly Movement | n/a |
| Capital Markets Industry Average Movement | 4.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Y30 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine Y30's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Trevor Vieweg | www.medbright.ai |
MedBright AI Investments Inc. invests in healthcare technology companies. The company was formerly known as Vinergy Capital Inc. and changed its name to MedBright AI Investments Inc. in November 2023. MedBright AI Investments Inc. was incorporated in 2001 and is headquartered in Vancouver, Canada.
MedBright AI Investments Inc. Fundamentals Summary
| Y30 fundamental statistics | |
|---|---|
| Market cap | €11.92m |
| Earnings (TTM) | -€4.96m |
| Revenue (TTM) | n/a |
-2.7x
P/S Ratio-2.3x
P/E RatioIs Y30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Y30 income statement (TTM) | |
|---|---|
| Revenue | -CA$6.18m |
| Cost of Revenue | CA$0 |
| Gross Profit | -CA$6.18m |
| Other Expenses | CA$1.12m |
| Earnings | -CA$7.31m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.067 |
| Gross Margin | 100.00% |
| Net Profit Margin | 118.19% |
| Debt/Equity Ratio | 5.3% |
How did Y30 perform over the long term?
See historical performance and comparison